Tranexamic Acid Pharmacology

Quick Answer

Tranexamic acid (TXA) is a synthetic lysine analogue antifibrinolytic agent that competitively inhibits plasminogen activation by blocking lysine-binding sites, thereby preventing fibrin clot degradation. TXA is approximately 8-10 times more potent than aminocaproic acid and represents the most extensively studied antifibrinolytic agent in modern medicine. Key pharmacokinetic features include rapid oral absorption (bioavailability 30-50%), minimal protein binding (<5%), predominant renal elimination (>95% excreted unchanged), and an elimination half-life of approximately 2-3 hours. The landmark CRASH-2 trial demonstrated a 1.5% absolute mortality reduction in trauma patients when TXA is administered within 3 hours of injury, establishing the critical time-dependent nature of its efficacy. Major clinical applications include trauma haemorrhage, obstetric haemorrhage (WOMAN trial), cardiac surgery, orthopaedic surgery, and heavy menstrual bleeding. Adverse effects are generally mild, but high-dose administration (particularly in cardiac surgery) is associated with dose-dependent seizure risk via GABA-A receptor antagonism. Contraindications include active thromboembolic disease, disseminated intravascular coagulation (DIC), and severe renal impairment (dose reduction required). Standard dosing in trauma is 1g loading dose followed by 1g infusion over 8 hours, while surgical dosing varies by indication. TXA is TGA-approved and PBS-listed in Australia for multiple indications. [1-10]

Pharmacology Overview

Chemical Classification and Structure

Tranexamic acid (trans-4-aminomethylcyclohexanecarboxylic acid, AMCHA) is a synthetic derivative of the amino acid lysine, classified as an antifibrinolytic agent within the broader category of haemostatic drugs. The molecular formula is C8H15NO2 with a molecular weight of 157.21 Da, making it a small, hydrophilic molecule. The chemical structure consists of a cyclohexane ring with an amino group (-NH2) and a carboxylic acid group (-COOH) attached at opposite positions (trans configuration), which is essential for its biological activity. The trans isomer is approximately 8 times more potent than the cis isomer due to optimal spatial orientation for binding to plasminogen. TXA is supplied as a white crystalline powder that is highly water-soluble (1:6 w/v in water at room temperature) and stable at physiological pH. Commercial preparations are available as 500mg tablets, 100mg/mL injectable solution (5mL and 10mL ampoules), and topical formulations. The drug is chemically stable when stored at room temperature and has a shelf life of 2-3 years depending on formulation. [11-15]

Molecular Mechanism of Action

Tranexamic acid exerts its antifibrinolytic effect through competitive inhibition of plasminogen activation, targeting the fibrinolytic cascade at a critical regulatory point. Plasminogen is the inactive zymogen precursor of plasmin, the primary enzyme responsible for fibrin degradation. Plasminogen contains five kringle domains, each possessing lysine-binding sites (LBS) that mediate attachment to fibrin clots. When plasminogen binds to fibrin via these lysine residues, tissue plasminogen activator (tPA) cleaves plasminogen to form active plasmin, which then degrades fibrin into soluble degradation products (D-dimers and fibrin degradation products). [16-20]

TXA, being a lysine analogue, competitively occupies the lysine-binding sites on plasminogen, preventing its attachment to fibrin. Without plasminogen binding to fibrin, tPA cannot efficiently convert plasminogen to plasmin, and fibrinolysis is inhibited. The inhibition constant (Ki) of TXA for plasminogen is approximately 10-100 µM, indicating high-affinity binding. Importantly, TXA does not directly inhibit plasmin activity but rather prevents plasmin generation at the site of clot formation. This mechanism preserves baseline fibrinolytic activity in the circulation while stabilising formed clots at sites of injury. [21-25]

At higher concentrations (>100 µg/mL), TXA may also directly inhibit plasmin through non-specific protease inhibition, though this is not the primary mechanism at therapeutic doses. Additionally, TXA inhibits the plasmin-mediated activation of complement, which may contribute to its anti-inflammatory properties observed in some clinical settings. [26-28]

The Fibrinolytic System: Context for TXA Action

Understanding TXA's mechanism requires appreciation of the fibrinolytic system's physiological role:

The net effect of TXA is stabilisation of fibrin clots by preventing their premature or excessive degradation, while maintaining systemic fibrinolytic capacity to prevent pathological thrombosis. This targeted mechanism explains the favourable safety profile observed in large trials such as CRASH-2, where TXA did not increase thromboembolic events despite potent antifibrinolytic activity. [29-32]

Structure-Activity Relationships

The antifibrinolytic potency of lysine analogues depends on their structural similarity to lysine and ability to occupy plasminogen LBS:

TXA's cyclohexane ring provides conformational rigidity that optimises binding to the hydrophobic pocket of plasminogen's lysine-binding sites. The trans configuration positions the amino and carboxyl groups at the correct distance (approximately 7 Å) to mimic the spacing of lysine's epsilon-amino group and alpha-carboxyl group. This structural optimisation explains TXA's 8-10 fold greater potency compared to the flexible, linear aminocaproic acid molecule. [33-35]

Pharmacokinetic Principles

Absorption

TXA demonstrates good oral bioavailability of 30-50%, with peak plasma concentrations (Cmax) achieved within 2-3 hours of oral administration. Absorption occurs primarily in the upper gastrointestinal tract and follows first-order kinetics. Food does not significantly affect the extent of absorption but may delay time to peak concentration by 30-60 minutes. The relatively low oral bioavailability compared to intravenous administration is attributed to incomplete intestinal absorption rather than first-pass hepatic metabolism, as TXA undergoes minimal hepatic metabolism. [36-40]

For intravenous administration, 100% bioavailability is achieved with immediate distribution into the plasma compartment. The plasma concentration-time profile following IV bolus administration shows a rapid distribution phase (alpha half-life 5-10 minutes) followed by a slower elimination phase. Intramuscular administration provides bioavailability approaching 100% with peak concentrations at 30-45 minutes. [41-43]

Topical application (to surgical wounds, mucous membranes) provides local concentrations sufficient for antifibrinolytic activity with minimal systemic absorption. This route is increasingly used in orthopaedic surgery, where topical TXA achieves wound concentrations 10-100 times higher than plasma concentrations after systemic administration. [44-46]

Distribution

TXA distributes rapidly throughout the extracellular fluid with a volume of distribution (Vd) of approximately 9-12 L (0.13-0.17 L/kg), approximating total body water. The small molecular size and hydrophilic nature allow free passage across capillary membranes into interstitial fluid. Protein binding is minimal (<3-5%), meaning that essentially all circulating TXA is pharmacologically active and available for tissue distribution. [47-50]

Tissue penetration studies demonstrate that TXA achieves therapeutic concentrations in:

• Synovial fluid: Reaches 50-100% of plasma concentration within 4-6 hours
• Cerebrospinal fluid: Low penetration (approximately 10% of plasma) but clinically significant in neurosurgery
• Aqueous humour: Adequate concentrations for ophthalmic indications
• Breast milk: Approximately 1% of maternal plasma concentration
• Placental transfer: Limited, with fetal:maternal ratio of approximately 0.1

The low CNS penetration at therapeutic doses explains why seizures are uncommon with standard dosing but become problematic at high doses used in cardiac surgery, where plasma concentrations may exceed the threshold for GABA receptor antagonism. [51-55]

Metabolism and Elimination

A critical pharmacokinetic feature of TXA is its minimal hepatic metabolism. Greater than 95% of an administered dose is excreted unchanged in the urine via glomerular filtration, with a small contribution from tubular secretion. The elimination half-life in patients with normal renal function is approximately 2-3 hours (range 1.5-3.5 hours depending on the study population). Total body clearance is approximately 100-120 mL/min, closely approximating glomerular filtration rate, confirming renal elimination as the predominant pathway. [56-60]

The minor metabolic pathway (<5% of dose) involves deamination to form a dicarboxylic acid metabolite, which is pharmacologically inactive. There is no involvement of cytochrome P450 enzymes, and no significant drug-drug interactions related to hepatic metabolism have been identified. [61-63]

Renal Impairment

The dependence on renal elimination has profound implications for patients with kidney disease:

In patients with severe renal impairment (CrCl <30 mL/min), accumulation of TXA occurs with repeated dosing, increasing the risk of adverse effects including seizures. Dose reduction proportional to the degree of renal impairment is recommended, though specific guidance varies between sources. TXA is effectively removed by haemodialysis, and supplemental dosing after dialysis sessions may be required if ongoing therapy is indicated. [64-68]

Hepatic Impairment

Given the minimal hepatic metabolism of TXA, dose adjustment is generally not required in patients with hepatic impairment. However, patients with severe liver disease may have underlying coagulopathy that affects the clinical decision to use antifibrinolytic therapy, and the risk-benefit balance should be carefully considered. [69-70]

Special Populations

Pregnancy: TXA crosses the placenta to a limited extent (fetal:maternal ratio approximately 0.1). The WOMAN trial established safety in obstetric haemorrhage, with no increase in adverse fetal outcomes. It is classified as Category B1 in Australia (animal studies show no fetal harm, limited human data). [71-73]

Paediatric Patients: Pharmacokinetics are similar to adults on a weight-normalised basis. Clearance may be slightly higher in children due to relatively larger renal mass. Weight-based dosing (10-20 mg/kg) provides adequate plasma concentrations. [74-76]

Elderly Patients: Age-related decline in renal function necessitates dose adjustment based on creatinine clearance. No other age-specific pharmacokinetic changes have been identified. [77-78]

Obesity: TXA distributes into total body water, which increases with obesity. Some authors recommend dosing based on ideal body weight, though clinical trials have used actual body weight without apparent problems. [79-80]

Pharmacodynamics

Dose-Response Relationships

The antifibrinolytic effect of TXA follows a sigmoid Emax model, with plasma concentrations of 5-10 µg/mL required for 80% inhibition of fibrinolysis in ex vivo studies. At concentrations above 100 µg/mL, near-complete inhibition of plasminogen activation is achieved, but additional clinical benefit is minimal while adverse effect risk increases. [81-83]

Standard dosing regimens (1g IV or 15-20 mg/kg) achieve peak plasma concentrations of 15-50 µg/mL, well within the therapeutic range. The duration of effect extends beyond the plasma half-life due to tissue binding and accumulation at the site of clot formation. [84-86]

Effects on Haemostasis

TXA's primary pharmacodynamic effect is stabilisation of fibrin clots, but it has broader effects on haemostasis:

Primary Effects:

• Inhibition of plasminogen-fibrin binding
• Reduced plasmin generation at clot sites
• Stabilisation of formed fibrin clots
• Reduced fibrin degradation products (D-dimers)

Secondary Effects:

• Inhibition of plasmin-mediated complement activation
• Reduced inflammatory mediator release
• Possible platelet function preservation (indirect)

Laboratory Effects:

• Decreased D-dimer levels
• Reduced fibrin degradation products
• No effect on prothrombin time (PT) or activated partial thromboplastin time (aPTT)
• May interfere with fibrinolytic assays [87-92]

GABA Receptor Antagonism and Seizure Risk

At high plasma concentrations (typically >100-150 µg/mL), TXA exhibits antagonistic activity at GABA-A receptors in the central nervous system. This off-target effect occurs because the molecular structure of TXA allows binding to the GABA recognition site, competitively inhibiting the inhibitory neurotransmitter GABA. The result is neuronal hyperexcitability and lowered seizure threshold. [93-97]

This mechanism explains the dose-dependent seizure risk observed primarily in cardiac surgery, where total TXA doses of 50-100 mg/kg have been associated with seizure incidence of 3-7%. Risk factors for TXA-associated seizures include:

• High total dose (>50 mg/kg)
• Bolus administration of large doses
• Renal impairment (reduced clearance)
• Open cardiac surgery (disrupted blood-brain barrier)
• Advanced age
• History of seizure disorder

The seizures are typically generalized tonic-clonic, occur postoperatively (often during emergence or in the ICU), and are usually self-limiting or responsive to benzodiazepines. Prophylactic levetiracetam has been studied but is not routinely recommended. [98-102]

Time-Dependent Efficacy

A critical pharmacodynamic concept established by the CRASH-2 trial analysis is the time-dependent efficacy of TXA in trauma. The benefit of TXA diminishes with increasing time from injury, and administration beyond 3 hours may be harmful:

This time-dependency likely reflects the evolution of trauma-induced coagulopathy and the transition from hyperfibrinolysis (early) to hypofibrinolysis (late). Early TXA stabilises clots during the hyperfibrinolytic phase, while late TXA may inhibit beneficial fibrinolysis required to maintain microvascular patency. [103-107]

Clinical Pharmacology and Evidence Base

Trauma Haemorrhage: CRASH-2 Trial

The Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2 (CRASH-2) trial is the landmark study establishing TXA as standard of care in trauma. This international, randomised, placebo-controlled trial enrolled 20,211 adult trauma patients with significant haemorrhage or risk of significant haemorrhage across 274 hospitals in 40 countries. [108]

Key Results:

• All-cause mortality: 14.5% TXA vs 16.0% placebo (RR 0.91, 95% CI 0.85-0.97, p=0.0035)
• Death due to bleeding: 4.9% TXA vs 5.7% placebo (RR 0.85, 95% CI 0.76-0.96)
• No increase in vascular occlusive events (1.7% vs 2.0%)
• Absolute risk reduction: 1.5% (NNT = 67)

Time-Dependent Subgroup Analysis (PMID: 21447024):

• Treatment within 1 hour: Death due to bleeding reduced from 7.7% to 5.3%
• Treatment 1-3 hours: Death due to bleeding reduced from 6.1% to 4.8%
• Treatment >3 hours: Death due to bleeding INCREASED from 3.1% to 4.4%

The CRASH-2 protocol uses TXA 1g IV loading dose over 10 minutes, followed by 1g infusion over 8 hours. This regimen has become the international standard for trauma haemorrhage management. [109-112]

Obstetric Haemorrhage: WOMAN Trial

The World Maternal Antifibrinolytic (WOMAN) trial randomised 20,060 women with postpartum haemorrhage (PPH) to TXA 1g IV or placebo across 193 hospitals in 21 countries. [113]

Key Results:

• Death due to bleeding: 1.5% TXA vs 1.9% placebo (RR 0.81, 95% CI 0.65-1.00, p=0.045)
• All-cause mortality: 2.3% TXA vs 2.6% placebo (NS)
• Hysterectomy rate: No significant difference
• Thromboembolic events: No significant difference

Time-Dependent Effect:

• Treatment within 3 hours of delivery: Significant reduction in bleeding death
• Treatment >3 hours: No benefit observed

The WOMAN trial confirmed the importance of early administration, with guidelines now recommending TXA as a first-line treatment for PPH alongside uterotonics. [114-116]

Cardiac Surgery

TXA has been extensively studied in cardiac surgery, where cardiopulmonary bypass activates both coagulation and fibrinolysis. Multiple meta-analyses demonstrate:

• Reduced blood loss: Mean reduction 250-350 mL
• Reduced transfusion requirements: RR 0.62-0.70
• Reduced re-operation for bleeding: RR 0.45-0.65
• No increase in mortality or thromboembolic events

However, high-dose TXA regimens (50-100 mg/kg total) are associated with postoperative seizures (incidence 3-7% vs <1% with lower doses or placebo). Current recommendations favour lower-dose protocols (30 mg/kg loading, 2-15 mg/kg/hr infusion) to balance efficacy with seizure risk. [117-122]

Orthopaedic Surgery

TXA has become standard of care in major orthopaedic procedures, particularly total hip and knee arthroplasty:

Total Knee Arthroplasty:

• Blood loss reduction: 300-500 mL mean reduction
• Transfusion rate reduction: From 20-40% to 5-10%
• No increase in venous thromboembolism

Total Hip Arthroplasty:

• Blood loss reduction: 200-400 mL mean reduction
• Similar efficacy to knee arthroplasty

Dosing options:

• Intravenous: 1-2g pre-incision ± repeat dose
• Topical: 1-3g in wound prior to closure
• Combined IV + topical: May offer incremental benefit

Multiple systematic reviews confirm the safety and efficacy of TXA in orthopaedic surgery, with Cochrane reviews concluding that TXA reduces blood loss and transfusion without increasing thromboembolic risk. [123-128]

Neurosurgery Considerations

TXA use in neurosurgery requires careful consideration of the balance between reducing surgical bleeding and the risk of seizures:

Potential Benefits:

• Reduced intraoperative blood loss
• Improved surgical field visualisation
• Reduced transfusion requirements

Concerns:

• Seizure risk (particularly with high doses)
• Blood-brain barrier disruption may increase CNS exposure
• Limited high-quality evidence

The CRASH-3 trial examined TXA in traumatic brain injury and found a modest reduction in head injury-related death (18.5% vs 19.8%) in patients with mild-to-moderate TBI, with no clear benefit in severe TBI. [129-132]

Dosing Regimens Summary

Topical Administration

Topical TXA application directly to surgical wounds provides high local concentrations with minimal systemic absorption:

Advantages:

• Local concentration 10-100x higher than after systemic dosing
• Minimal systemic adverse effects
• Suitable for patients with contraindications to systemic TXA

Methods:

• Direct wound application: 1-3g in 20-100 mL saline
• Soaked sponge application
• Spray application

Evidence: Multiple RCTs in orthopaedic surgery demonstrate equivalent efficacy to intravenous administration with lower systemic drug exposure. [133-136]

Adverse Effects and Complications

Common Adverse Effects

TXA is generally well-tolerated, with most adverse effects being mild and self-limiting:

Rapid intravenous administration may cause transient hypotension due to vasodilation; this can be avoided by administering doses over 10 minutes or longer. [137-140]

Seizures

The most clinically significant adverse effect is seizures, which occur almost exclusively in the context of high-dose administration:

Risk Factors:

• Total dose >50 mg/kg
• Plasma concentration >100-150 µg/mL
• Renal impairment
• Open cardiac surgery
• Pre-existing seizure disorder
• Elderly patients

Clinical Characteristics:

• Typically generalized tonic-clonic
• Onset usually within 6-12 hours postoperatively
• Usually self-limiting or responsive to benzodiazepines
• May be refractory in some cases

Prevention:

• Use lowest effective dose
• Avoid bolus administration of large doses
• Adjust dose for renal function
• Consider alternative agents in high-risk patients

Management:

• Benzodiazepines (first-line)
• Levetiracetam or phenytoin (refractory cases)
• Supportive care [141-145]

Thromboembolic Events

Despite the theoretical concern that inhibiting fibrinolysis might promote thrombosis, large trials have consistently shown no increase in thromboembolic events:

CRASH-2 Results:

• Pulmonary embolism: 0.7% TXA vs 0.7% placebo
• Deep vein thrombosis: 0.4% TXA vs 0.4% placebo
• Stroke: 0.4% TXA vs 0.5% placebo
• Myocardial infarction: 0.3% TXA vs 0.4% placebo

This reassuring safety profile reflects TXA's mechanism of stabilising existing clots rather than promoting new thrombus formation, and the preservation of baseline systemic fibrinolytic activity. [146-148]

Contraindications

Absolute Contraindications:

• Active thromboembolic disease (DVT, PE, arterial thrombosis)
• Subarachnoid haemorrhage (risk of cerebral vasospasm and infarction)
• History of hypersensitivity to TXA

Relative Contraindications:

• Severe renal impairment (use with caution, dose adjustment)
• Disseminated intravascular coagulation (consumptive phase)
• History of seizures (consider risk-benefit)
• Acquired colour vision defects (rare association reported) [149-152]

Drug Interactions

TXA has minimal clinically significant drug interactions:

The most important interaction is with factor IX concentrates (used in haemophilia B), where the combination may result in thrombosis. TXA should generally be avoided or used with extreme caution in patients receiving these products. [153-156]

Comparison with Aminocaproic Acid

In clinical practice, TXA is preferred due to its greater potency (allowing lower doses), more extensive evidence base, and established protocols. Aminocaproic acid may be considered in patients at high seizure risk where antifibrinolytic therapy is still required, given its lower CNS penetration and weaker GABA antagonism. [157-160]

Australian/NZ Specific Considerations

TGA-Approved Formulations

Tranexamic acid is TGA-approved in Australia in multiple formulations:

Injectable:

• Cyklokapron® (Pfizer): 100 mg/mL solution in 5 mL ampoules (500 mg)
• Tranexamic acid generic: 100 mg/mL in 5 mL and 10 mL ampoules
• Pre-filled syringes available for trauma settings

Oral:

• Cyklokapron® tablets: 500 mg
• Generic tablets: 500 mg

Storage:

• Injection: Store below 25°C, protect from light
• Tablets: Store below 30°C
• Shelf life: 2-3 years depending on formulation

TXA injection is compatible with standard IV fluids (0.9% saline, Hartmann's solution) and can be added to infusion bags for continuous administration. [161-164]

PBS Listing

Tranexamic acid is listed on the Pharmaceutical Benefits Scheme (PBS) for the following indications:

General Schedule (non-restricted):

• Short-term use in patients with haemorrhagic conditions requiring antifibrinolytic therapy

Specific Indications:

• Menorrhagia (heavy menstrual bleeding)
• Hereditary angioedema prophylaxis
• Dental procedures in patients with bleeding disorders

Hospital Supply:

• Widely available in hospital formularies for surgical and trauma indications
• Not restricted by approval processes in most institutions
• Included in trauma resuscitation protocols nationally

The PBS subsidy makes TXA accessible and affordable for appropriate outpatient indications. Hospital use for surgical and trauma settings is through hospital pharmaceutical budgets. [165-168]

Australian Guidelines

Australian Resuscitation Council (ARC) Guidelines:

• TXA recommended as part of massive transfusion protocols
• Administration within 3 hours of injury emphasised
• Standard dose: 1g IV loading, 1g infusion over 8 hours

RANZCOG Guidelines (Obstetrics):

• TXA recommended for PPH not responding to uterotonics
• Administer within 3 hours of delivery
• Dose: 1g IV, may repeat once if bleeding continues

ANZCA Guidelines:

• TXA included in perioperative blood management strategies
• Supported for major orthopaedic and cardiac surgery
• Emphasis on appropriate patient selection and dosing [169-173]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Populations

Tranexamic acid pharmacotherapy in Aboriginal and Torres Strait Islander patients requires consideration of several factors unique to these populations. Higher rates of chronic kidney disease (CKD) - approximately 3-4 times the prevalence in non-Indigenous Australians - may affect TXA clearance and necessitate dose adjustment. Renal function should be assessed prior to TXA administration, particularly in older patients or those with known comorbidities such as diabetes or hypertension, which are also more prevalent in Indigenous communities.

The burden of trauma and injury is disproportionately higher in Aboriginal and Torres Strait Islander populations, making TXA potentially more frequently indicated. Pre-hospital administration of TXA through retrieval services and remote area nurse practitioners has been advocated to ensure timely treatment within the critical 3-hour window. Remote communities face challenges in accessing tertiary care, and early TXA administration during retrieval transport may be life-saving.

Cultural considerations include the importance of family involvement in treatment decisions and clear, culturally appropriate communication about the purpose of medications. Aboriginal Health Workers and interpreters should be engaged where available to support informed consent. Some communities may have concerns about blood products or interventions perceived as affecting the body's integrity, and respectful discussion of these concerns is important.

Women's health considerations are particularly relevant given TXA's use for heavy menstrual bleeding. Indigenous women may face barriers to accessing healthcare and discussing menstrual issues, and culturally safe, women-only spaces and female healthcare providers may facilitate appropriate treatment.

Maori Health Considerations (New Zealand)

Maori patients have higher rates of cardiovascular disease, diabetes, and chronic kidney disease, which may influence TXA prescribing decisions. The principles of whanaungatanga (relationship building) and manaakitanga (hospitality, care) support patient-centred communication that includes whanau (extended family) in treatment discussions.

Rural Maori communities, particularly in areas like Te Tai Tokerau (Northland) and Te Tai Rawhiti (East Coast), may face delays in accessing tertiary care. Early TXA administration through ambulance services and rural practitioners is important for ensuring treatment within the therapeutic time window. Tikanga (cultural protocols) should be respected, and Maori health workers or interpreters engaged where appropriate. [174-178]

ANZCA Primary Exam Focus

Common MCQ Patterns

ANZCA Primary MCQs frequently test the following TXA concepts:

1. Mechanism of action: Competitive inhibition of lysine-binding sites on plasminogen (NOT direct plasmin inhibition)
2. Structure: Synthetic lysine analogue, trans-cyclohexane configuration
3. Pharmacokinetics: Renal elimination (>95% unchanged), half-life 2-3 hours, minimal protein binding
4. Potency comparison: 8-10 times more potent than aminocaproic acid
5. Time-dependent efficacy: CRASH-2 evidence - benefit within 3 hours, potential harm after 3 hours
6. Seizure mechanism: GABA-A receptor antagonism at high concentrations
7. Contraindications: Active thromboembolism, DIC, subarachnoid haemorrhage

Primary Viva Question Themes

Viva scenarios typically explore:

• Mechanism of action and fibrinolytic system physiology
• CRASH-2 trial results and clinical implications
• Time-dependent efficacy and the 3-hour rule
• Dosing regimens for different indications
• Comparison with aminocaproic acid
• Management of TXA-associated seizures
• Special populations: renal impairment, obstetric patients

Calculation Questions

Candidates should be comfortable with:

• Calculating weight-based TXA doses
• Understanding plasma concentration targets
• Adjusting doses for renal impairment
• Converting between mg/kg and total doses

Example: A 70 kg trauma patient requires TXA per CRASH-2 protocol. Calculate the loading dose and infusion rate.

• Loading: 1g over 10 minutes (fixed dose per protocol)
• Infusion: 1g over 8 hours = 125 mg/hr (1000 mg ÷ 8 hr)

Example: A patient weighing 80 kg requires TXA for cardiac surgery. The protocol calls for 30 mg/kg loading dose. Calculate the dose.

• 30 mg/kg × 80 kg = 2,400 mg = 2.4 g

Assessment Content

SAQ Practice Question (20 marks)

Question:

A 35-year-old woman weighing 65 kg presents to the emergency department following a motor vehicle accident with obvious long bone fractures and suspected intra-abdominal injury. Her blood pressure is 85/50 mmHg, heart rate 130 bpm, and she has received 2 litres of crystalloid. Estimated blood loss is 2 litres and she is being prepared for emergency laparotomy. The trauma team requests tranexamic acid.

(a) Describe the mechanism of action of tranexamic acid at the molecular level, including its interaction with the fibrinolytic system. (6 marks)

(b) Outline the evidence from the CRASH-2 trial that supports the use of tranexamic acid in this scenario, including the time-dependent effect on outcomes. (6 marks)

(c) Calculate the appropriate TXA dosing regimen for this patient according to the CRASH-2 protocol, and explain the rationale for this dosing schedule. (4 marks)

(d) The patient has a history of epilepsy. Discuss the relevant considerations for TXA use in this patient. (4 marks)

---

Model Answer:

(a) Mechanism of Action (6 marks)

Fibrinolytic system overview (2 marks):

• Plasminogen is the inactive precursor of plasmin, the enzyme that degrades fibrin clots
• Plasminogen binds to fibrin via lysine-binding sites (LBS) on its kringle domains
• Tissue plasminogen activator (tPA) cleaves fibrin-bound plasminogen to active plasmin
• Plasmin degrades fibrin into soluble degradation products (D-dimers, FDPs)

TXA mechanism (2 marks):

• TXA is a synthetic lysine analogue with a trans-cyclohexane structure
• TXA competitively binds to lysine-binding sites on plasminogen
• This prevents plasminogen from attaching to fibrin

Effect on haemostasis (2 marks):

• Without plasminogen-fibrin binding, plasmin cannot be efficiently generated at clot sites
• Formed fibrin clots are stabilised and protected from premature degradation
• Systemic fibrinolytic capacity is preserved, explaining lack of increased thrombosis risk

(b) CRASH-2 Evidence (6 marks)

Trial design (1 mark):

• International RCT, 20,211 trauma patients with significant haemorrhage
• TXA 1g loading + 1g infusion vs placebo

Primary outcomes (2 marks):

• All-cause mortality: 14.5% TXA vs 16.0% placebo (RR 0.91, p=0.0035)
• Death due to bleeding: 4.9% TXA vs 5.7% placebo (RR 0.85)
• Absolute risk reduction 1.5%, NNT = 67

Safety (1 mark):

• No increase in vascular occlusive events (VTE, PE, MI, stroke)
• Similar adverse event profile to placebo

Time-dependent effect (2 marks):

• Treatment <1 hour: Greatest mortality benefit
• Treatment 1-3 hours: Moderate benefit
• Treatment >3 hours: Increased risk of death due to bleeding
• This reflects transition from hyperfibrinolysis (early trauma) to hypofibrinolysis (late)
• Current recommendation: Administer within 3 hours or not at all

(c) Dosing Regimen (4 marks)

CRASH-2 protocol (2 marks):

• Loading dose: 1g IV over 10 minutes (fixed dose, not weight-based)
• Maintenance infusion: 1g IV over 8 hours

Rationale (2 marks):

• Fixed 1g dose achieves therapeutic plasma concentrations (15-50 µg/mL) in most patients
• Loading dose provides rapid peak concentration
• 8-hour infusion maintains concentration during the critical period of hyperfibrinolysis
• Total dose 2g provides antifibrinolytic effect without exceeding seizure threshold

(d) Epilepsy Considerations (4 marks)

Seizure mechanism (1 mark):

• TXA antagonises GABA-A receptors at high plasma concentrations (>100 µg/mL)
• Risk is dose-dependent and uncommon at CRASH-2 protocol doses

Risk assessment (1.5 marks):

• Pre-existing epilepsy increases theoretical seizure risk
• Standard trauma doses (2g total) rarely achieve concentrations causing seizures
• Risk significantly lower than high-dose cardiac surgery protocols (50-100 mg/kg)

Management approach (1.5 marks):

• Benefits of TXA in severe haemorrhage likely outweigh seizure risk
• Ensure patient is not receiving contraindicated medications
• Monitor for seizure activity perioperatively
• Ensure antiepileptic medication levels are therapeutic
• Have benzodiazepines readily available

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Examiner: You are the anaesthetist for a 72-year-old man undergoing coronary artery bypass grafting. The surgeon asks you to administer tranexamic acid to reduce bleeding. How would you approach this request?

Candidate:

Initial Assessment (3 marks):

"I would consider TXA as it has strong evidence for reducing blood loss and transfusion in cardiac surgery. Before administering, I would review several factors:

First, I would check for contraindications - active thromboembolic disease, recent stroke, or known hypersensitivity. I would review his renal function, as TXA is renally eliminated and accumulates in renal impairment.

Second, I would assess seizure risk factors. At 72 years old, this patient has some risk factors for TXA-associated seizures - age-related decline in renal function and open cardiac surgery with potential blood-brain barrier disruption."

Examiner: His creatinine is 120 µmol/L (eGFR 55 mL/min/1.73m²). What dosing would you use?

Candidate:

Dosing Considerations (4 marks):

"With mildly reduced renal function (eGFR 55), I would use a moderate-dose protocol rather than high-dose. High-dose TXA protocols (50-100 mg/kg total) are associated with seizure rates of 3-7%, while lower-dose protocols have much lower risk.

I would administer:

• Loading dose: 10-20 mg/kg over 20 minutes (approximately 700-1400 mg for a 70 kg patient)
• Maintenance infusion: 1-2 mg/kg/hr throughout surgery
• Consider adding 1g to the pump prime

This provides antifibrinolytic efficacy while keeping plasma concentrations below the seizure threshold. I would avoid bolus administration of large doses, which produces high peak concentrations."

Examiner: Postoperatively in ICU, the patient has a witnessed generalised tonic-clonic seizure. How would you manage this?

Candidate:

Seizure Management (4 marks):

"I would follow a systematic approach:

Immediate management:

• Protect the airway - the patient is likely already intubated post-cardiac surgery
• Administer supplemental oxygen
• Obtain IV access if not already present
• Ensure patient safety

First-line treatment:

• Benzodiazepine: Midazolam 2-5 mg IV or diazepam 5-10 mg IV
• This should terminate most TXA-associated seizures

If seizure continues:

• Repeat benzodiazepine after 5 minutes
• Consider levetiracetam 1000-2000 mg IV or phenytoin loading dose

Investigation:

• Check blood glucose, electrolytes, arterial blood gas
• Review TXA total dose administered
• Consider CT head if seizures are prolonged or focal features present

Documentation and follow-up:

• Document the event and timing in relation to TXA administration
• Inform the patient once recovered
• Consider neurological consultation if recurrent seizures"

Examiner: What would you tell the family about this complication?

Candidate:

Communication (4 marks):

"I would have an honest, compassionate conversation with the family:

I would explain that their father experienced a seizure after his surgery, which has now resolved with treatment. I would explain that one of the medications we use to reduce bleeding during heart surgery - tranexamic acid - can occasionally cause seizures, particularly after open heart surgery.

I would reassure them that:

• This is a recognised complication
• The seizure has been controlled
• We are monitoring him closely
• Most patients recover fully without lasting effects

I would explain that TXA was used because the benefits in reducing bleeding during cardiac surgery are well-established, but like all medications, it has potential side effects. The decision to use it was based on weighing these risks and benefits.

I would invite questions and provide ongoing updates as his condition evolves."

Total: 15 marks

---

Additional Clinical Applications

Heavy Menstrual Bleeding

Tranexamic acid is highly effective for the treatment of heavy menstrual bleeding (menorrhagia), providing an alternative to hormonal therapies for women who prefer non-hormonal options or have contraindications to hormonal treatment.

Evidence Base:

• Systematic reviews demonstrate 30-55% reduction in menstrual blood loss
• Comparable efficacy to NSAIDs and superior to placebo
• No effect on cycle length or fertility
• Well-tolerated with minimal adverse effects

Dosing:

• 1g PO three times daily (TDS) during menstruation
• Maximum duration 4 days per cycle
• Can be used for multiple consecutive cycles

TGA/PBS Listing:

• Listed on PBS for menorrhagia
• Available as Cyklokapron® 500mg tablets (2 tablets TDS)
• Generic formulations also available

Dental Procedures in Bleeding Disorders

TXA is valuable for dental procedures in patients with inherited or acquired bleeding disorders, reducing the need for factor replacement therapy:

Indications:

• Haemophilia A and B
• von Willebrand disease
• Patients on anticoagulant therapy
• Thrombocytopenia

Administration:

• Systemic: 25 mg/kg PO or 10 mg/kg IV pre-procedure
• Topical: 4.8% mouthwash (10 mL, swish and spit QID for 7 days)
• Combined approach often used

Evidence:

• Reduces need for blood product support
• Decreases postoperative bleeding complications
• Safe in combination with factor replacement

Hereditary Angioedema

TXA has a role in long-term prophylaxis of hereditary angioedema (HAE), though newer targeted therapies have largely superseded it:

Mechanism:

• HAE involves uncontrolled activation of contact/kallikrein system
• Plasmin activates factor XII, which can trigger bradykinin generation
• TXA may reduce attack frequency by inhibiting plasmin-mediated factor XII activation

Dosing:

• 1-1.5g PO two to three times daily for prophylaxis
• Less effective than C1-inhibitor concentrate for acute attacks

Epistaxis

Topical TXA is effective for anterior epistaxis management:

Application:

• TXA-soaked cotton pledget or nasal packing
• Concentration: 100 mg/mL (injectable solution) or 500 mg crushed tablet in 5 mL saline
• Duration: 10-20 minutes of direct pressure

Evidence:

• Randomised trials show faster bleeding cessation
• Reduced need for nasal packing
• Particularly useful for anticoagulated patients

Gastrointestinal Bleeding

TXA has been studied in upper gastrointestinal bleeding, though evidence is less robust than for trauma:

HALT-IT Trial:

• Large RCT (12,009 patients) examining TXA in acute GI bleeding
• No significant reduction in death due to bleeding
• No increase in thromboembolic events
• TXA not routinely recommended for GI bleeding based on this trial

Traumatic Brain Injury: CRASH-3

The CRASH-3 trial specifically examined TXA in traumatic brain injury (TBI):

Trial Design:

• 12,737 patients with TBI and intracranial bleeding on CT
• TXA 1g loading + 1g over 8 hours vs placebo

Key Results:

• Head injury-related death: 18.5% TXA vs 19.8% placebo (RR 0.94, p=0.057)
• Benefit most apparent in mild-to-moderate TBI (GCS 9-15)
• No benefit in severe TBI (GCS 3-8)
• No increase in thromboembolic events

Clinical Implications:

• Early TXA may be beneficial in mild-to-moderate TBI
• Less clear benefit in severe TBI
• Reinforces importance of early administration (<3 hours)

Pre-Hospital and Remote Area Administration

Ambulance Service Protocols

TXA administration by paramedics in the pre-hospital setting has been implemented across Australian ambulance services:

Indications:

• Major trauma with signs of significant haemorrhage
• Systolic BP <90 mmHg or signs of shock
• Estimated blood loss >500 mL
• Time from injury <3 hours

Administration:

• 1g IV/IO as slow push over 10 minutes
• Can be diluted in 100 mL saline for infusion
• Intramuscular route acceptable if IV access delayed

Benefits:

• Ensures treatment within critical time window
• Particularly valuable in rural/remote settings with prolonged transport
• Simple, standardised protocol

Retrieval Medicine Applications

For aeromedical retrieval services (Royal Flying Doctor Service, retrieval networks):

Considerations:

• TXA should be administered early, not delayed for retrieval arrival
• Pre-hospital notification allows hospital preparation
• Documentation of time of injury and TXA administration critical
• Continuation of infusion during transport if indicated

Remote Area Challenges:

• Limited IV access capability in some settings
• IM administration may be necessary
• Remote area nurses increasingly trained in TXA administration

Perioperative Blood Management Context

Patient Blood Management Principles

TXA fits within the broader framework of Patient Blood Management (PBM), a multimodal approach to minimising blood loss and transfusion:

Three Pillars of PBM:

1. Optimise red cell mass (treat preoperative anaemia)
2. Minimise blood loss (surgical technique, antifibrinolytics, cell salvage)
3. Optimise physiological tolerance of anaemia

TXA's Role:

• Primary pharmacological agent for minimising perioperative blood loss
• Complements surgical haemostasis techniques
• Reduces transfusion-associated risks

Cost-Effectiveness

TXA is highly cost-effective given its low acquisition cost and significant clinical benefits:

Economic Considerations:

• TXA cost: Approximately $2-5 AUD per gram
• Packed red blood cell unit: $400-500 AUD
• Reduction of even one transfusion provides substantial cost savings
• Additional savings from reduced complications (shorter ICU stay, fewer infections)

Number Needed to Treat:

• CRASH-2: NNT = 67 to prevent one death
• Orthopaedic surgery: NNT = 5-10 to prevent one transfusion
• Cardiac surgery: NNT = 4-8 to prevent one transfusion

Monitoring and Laboratory Considerations

Effect on Coagulation Tests

TXA does not directly affect standard coagulation tests:

Viscoelastic Testing

Point-of-care viscoelastic tests (TEG, ROTEM) can demonstrate TXA effect:

ROTEM Changes:

• Increased maximum clot firmness (MCF)
• Prolonged clot lysis time
• Reduced fibrinolysis parameters

TEG Changes:

• Increased maximum amplitude (MA)
• Reduced LY30 (percent lysis at 30 minutes)

These tests can guide antifibrinolytic therapy in massive transfusion protocols, though empirical early TXA administration remains the primary approach.

Second Viva Scenario

Primary Viva Scenario 2 (15 marks)

Examiner: A 28-year-old woman at 38 weeks gestation has undergone emergency caesarean section for placenta praevia. Despite delivery of the baby and placenta, she continues to bleed heavily. The estimated blood loss is now 2.5 litres. The obstetrician asks about tranexamic acid. How would you advise?

Candidate:

Initial Assessment (3 marks):

"This is a case of major postpartum haemorrhage (PPH), defined as blood loss >1000 mL after caesarean section or blood loss causing haemodynamic instability. With 2.5 litres blood loss, this qualifies as massive PPH.

I would recommend tranexamic acid as part of the multimodal management. The WOMAN trial provides strong evidence for TXA in PPH, demonstrating a reduction in death due to bleeding when administered early."

Examiner: What dose would you recommend and what is the evidence?

Candidate:

Evidence and Dosing (4 marks):

"The WOMAN trial randomised over 20,000 women with PPH to TXA 1g IV or placebo. Key findings:

• Death due to bleeding: 1.5% TXA vs 1.9% placebo (relative risk 0.81)
• No increase in thromboembolic events
• Greatest benefit when given within 3 hours of delivery

I would recommend:

• 1g TXA IV over 10 minutes
• If bleeding continues after 30 minutes, or if bleeding stops and restarts within 24 hours, a second dose of 1g can be given
• Maximum total dose: 2g

The dose is fixed, not weight-based, consistent with the WOMAN trial protocol."

Examiner: What other management would you institute simultaneously?

Candidate:

Comprehensive PPH Management (4 marks):

"TXA is one component of a multimodal approach:

Resuscitation:

• Large-bore IV access, arterial line for monitoring
• Activate massive transfusion protocol
• Warm fluids, blood products (PRBC, FFP, platelets, cryoprecipitate)
• Vasopressors if required

Uterotonics:

• Oxytocin infusion (continue if already running, or 5 IU IV slowly)
• Ergometrine 250 mcg IM (if no contraindications)
• Carboprost (Hemabate) 250 mcg IM
• Misoprostol 800-1000 mcg sublingual/rectal

Surgical/Procedural:

• Bimanual uterine compression
• Uterine balloon tamponade (Bakri balloon)
• B-Lynch suture or other compression sutures
• Uterine artery ligation/embolisation
• Hysterectomy as last resort

Correct coagulopathy:

• Target fibrinogen >2 g/L (may need cryoprecipitate or fibrinogen concentrate)
• Maintain platelets >50 × 10⁹/L
• Correct hypothermia and acidosis"

Examiner: The bleeding is controlled but the patient has now received 6 units of packed red blood cells and 4 units of FFP. Her postoperative creatinine is 180 µmol/L (baseline 60). Any concerns about the TXA?

Candidate:

Renal Considerations (4 marks):

"The elevated creatinine indicates acute kidney injury, likely from hypoperfusion during the haemorrhagic shock.

Regarding TXA:

• TXA is eliminated >95% unchanged by the kidneys
• With AKI, clearance will be reduced and half-life prolonged
• However, TXA has already been administered and no further doses should be needed now bleeding is controlled

Key considerations:

• Monitor for signs of TXA accumulation (unlikely with single 1-2g dose)
• The seizure risk with TXA is dose-dependent and primarily seen with high-dose regimens
• The doses used in obstetric haemorrhage (1-2g) rarely cause seizures even with renal impairment
• Monitor renal function recovery - expect improvement as resuscitation continues
• If further TXA were needed (unlikely), I would use caution and potentially reduce the dose

The benefit of TXA in this life-threatening haemorrhage far outweighed the risks, and the development of AKI does not indicate the TXA caused harm - it reflects the severity of the haemorrhagic shock."

Total: 15 marks

References

1. Tengborn L, Blombäck M, Berntorp E. Tranexamic acid--an old drug still going strong and making a revival. Thromb Res. 2015;135(2):231-242. PMID: 25559460

2. McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72(5):585-617. PMID: 22397329

3. Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. PMID: 20554319

4. Roberts I, Shakur H, Coats T, et al. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. Health Technol Assess. 2013;17(10):1-79. PMID: 23477634

5. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. PMID: 28456509

6. Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017;376(2):136-148. PMID: 27774838

7. Roberts I, Shakur H, Afolabi A, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101. PMID: 21439633

8. Ker K, Edwards P, Perel P, et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. PMID: 22611164

9. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007;356(22):2301-2311. PMID: 17538089

10. Levy JH. Antifibrinolytic therapy: new data and new concepts. Lancet. 2010;376(9734):3-4. PMID: 20554318

11. Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999;57(6):1005-1032. PMID: 10400410

12. Okamoto S, Sato S, Takada Y, Okamoto U. An active stereo-isomer (trans-form) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med. 1964;13:177-185. PMID: 14328960

13. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29(3):236-261. PMID: 2581933

14. Astedt B. Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl. 1987;137:22-25. PMID: 3321402

15. Hoylaerts M, Lijnen HR, Collen D. Studies on the mechanism of the antifibrinolytic action of tranexamic acid. Biochim Biophys Acta. 1981;673(1):75-85. PMID: 7193484

16. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thromb Haemost. 2005;93(4):647-654. PMID: 15841308

17. Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost. 2009;7(1):4-13. PMID: 19017261

18. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3):307-321. PMID: 15842654

19. Chapin JC, Hajjar KA. Fibrinolysis and the control of blood coagulation. Blood Rev. 2015;29(1):17-24. PMID: 25294122

20. Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 2015;13 Suppl 1:S98-105. PMID: 26149056

21. Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature. 1978;272(5653):549-550. PMID: 148686

22. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983;258(7):4249-4256. PMID: 6833254

23. Markus G. The relevance of plasminogen activator binding to the fibrinolytic mechanism. Fibrinolysis. 1996;10:61-72.

24. Thorsen S. The mechanism of plasminogen activation and the variability of the fibrin effector during tissue-type plasminogen activator-mediated fibrinolysis. Ann N Y Acad Sci. 1992;667:52-63. PMID: 1309053

25. Medcalf RL. Fibrinolysis, inflammation, and regulation of the plasminogen activating system. J Thromb Haemost. 2007;5 Suppl 1:132-142. PMID: 17635719

26. Barthel D, Schindler S, Zipfel PF. Plasminogen is a complement inhibitor. J Biol Chem. 2012;287(22):18831-18842. PMID: 22427648

27. Jimenez JJ, Iribarren JL, Lorber C, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: a case control study followed by a randomized double-blind controlled trial. Crit Care. 2007;11(6):R117. PMID: 17988381

28. Godier A, Roberts I, Hunt BJ. Tranexamic acid: less bleeding and less thrombosis? Crit Care. 2012;16(3):135. PMID: 22715923

29. Napolitano LM, Cohen MJ, Cotton BA, et al. Tranexamic acid in trauma: how should we use it? J Trauma Acute Care Surg. 2013;74(6):1575-1586. PMID: 23694890

30. Hunt BJ, Allard S, Keeling D, et al. A practical guideline for the haematological management of major haemorrhage. Br J Haematol. 2015;170(6):788-803. PMID: 26147359

31. Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg. 2012;147(2):113-119. PMID: 22006852

32. Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev. 2015;5:CD004896. PMID: 25993352

33. Andersson L, Nilsson IM, Niléhn JE, et al. Experimental and clinical studies on AMCHA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol. 1965;2(3):230-247. PMID: 5834403

34. Melander B, Gliniecki G, Granstrand B, Hanshoff G. Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA (a comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copenh). 1965;22(4):340-352. PMID: 4379172

35. Sander M, Spies CD, Martiny V, et al. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care. 2010;14(4):R148. PMID: 20682050

36. Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1):65-72. PMID: 7308268

37. Eriksson O, Kjellman H, Pilbrant A, Schannong M. Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers. Eur J Clin Pharmacol. 1974;7(5):375-380. PMID: 4422030

38. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78(12):3114-3124. PMID: 1742478

---

This content is designed for ANZCA Primary Examination preparation. Always verify current guidelines and local protocols.